Areas of Focus

img

Portfolio prioritization

Multiple stakeholders from discovery, development, commercial have different views. Outside views, when sought, conflict with internal views.

img

Assessing in-licensing & investment opportunities

BD&L teams seek the outside view from those outside BD&L — stakeholders throughout the company. They also tap external relationships, but miss the diversity of larger networks.

img

Indication strategy choices

Which indications hold the most promise? Which are the quickest route to regulatory approval?

img

Protocol design

There are more analytics-based approaches all the time, leveraging machine learning to assess the impact of inclusion/exclusion criteria on success. Diverse expertise is critical to assess what the analytics say.

img

Sales Forecasting

Assessing the commercial potential of a new drug is an area where machine learning on its own provides almost no insight. Collective intelligence can really shine here.